Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group (NYSE: CI) files a broad range of documents with the U.S. Securities and Exchange Commission that together provide a detailed view of its operations as a global health company. These SEC filings cover its activities across Cigna Healthcare and Evernorth Health Services, including health insurance, pharmacy benefit services, specialty pharmacy, care services, and related health solutions.
On this page, you can review current and historical 10-K and 10-Q reports to understand how The Cigna Group describes its business segments, risk factors, and financial performance over time. These filings typically break out results for Evernorth Health Services, Cigna Healthcare, and Corporate and Other Operations, and they explain non-GAAP measures such as adjusted income from operations that management uses to evaluate underlying trends.
The Cigna Group also submits frequent Form 8-K reports. Recent examples include 8-K filings announcing quarterly earnings results, affirmations of full-year outlook, changes to Board committee structures, Board appointments and retirements, and the issuance of senior notes with details on interest rates, maturities, and intended use of proceeds. These current reports highlight material events such as capital markets transactions and governance changes.
Debt offerings and related agreements are documented through exhibits to 8-K filings, including underwriting agreements, supplemental indentures, and legal opinions. These materials outline the terms of senior notes and the covenants that apply to The Cigna Group’s indebtedness.
Using this page, you can access real-time updates from EDGAR alongside AI-powered summaries that explain the key points of lengthy filings in plain language. AI analysis can help you quickly identify segment performance drivers in 10-Qs and 10-Ks, interpret the implications of new debt issuances, and understand governance or committee changes disclosed in 8-Ks. You can also review any Form 4 insider transaction reports, when available, to see how directors and executives are trading CI shares.
For investors, analysts, and researchers, The Cigna Group’s SEC filings provide a structured record of its financial condition, strategic initiatives, risk disclosures, and corporate governance framework, and this page brings those documents together with tools to make them easier to interpret.
Cigna Group EVP and CFO Ann M. Dennison reported equity compensation changes involving company stock. She received an award of 8,066 employee stock options with an exercise price of $0.0000, which vest in three equal annual installments beginning on March 1, 2027. She was also granted 5,234 shares of common stock as restricted shares that vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations upon the vesting of restricted shares, 409 shares of common stock were disposed of at $287.55 per share through share withholding, leaving her with 7,745 common shares held directly.
The Cigna Group Chairman & CEO David Cordani reported new equity awards and related tax withholdings. He was granted 37,516 employee stock options at an exercise price of $0, vesting in three equal annual installments beginning March 1, 2027.
He also acquired 23,788 shares of common stock from settlement of strategic performance shares for the 2023–2025 period and 17,389 restricted shares that vest in three equal annual installments beginning March 1, 2027. To cover tax obligations on these awards, 11,024 and 4,408 shares were disposed of at $287.55 per share. The filing also lists indirect holdings in common stock through a trust, a GRAT, and ongoing participation in The Cigna Group's 401(k) Plan.
The Cigna Group director George Kurian increased his deferred compensation stake through a grant of phantom stock units. On this Form 4, he acquired 103.5125 phantom stock units on February 27, 2026 as a grant, bringing his total phantom stock unit holdings to 1,803.6672.
The units reflect a voluntary deferral of a portion of his cash retainer into a hypothetical stock fund under Cigna’s Deferred Compensation Plan of 2005 for directors. Each phantom stock unit is the economic equivalent of one share of Cigna common stock and will be settled in cash. The total includes 9.3181 phantom stock units credited through a dividend reinvestment feature of the plan.
The Cigna Group announced a planned leadership transition and reaffirmed its 2026 financial outlook. Brian C. Evanko, currently president and chief operating officer, will become chief executive officer on July 1, 2026, succeeding David M. Cordani, who will retire as CEO and become executive chair of the board.
The board also elected Evanko as a director effective April 1, 2026, and named Eric J. Foss lead independent director, while revising committee leadership across audit, governance, finance and technology, and people resources. Effective July 1, 2026, Evanko’s compensation will include a $1,300,000 base salary, a $2,600,000 Enterprise Incentive Plan target and a $15,100,000 long‑term incentive target, plus a one‑time $3,500,000 transitional equity award tied to assuming the CEO role. Cordani, as executive chair, will receive a $1,000,000 base salary and a $2,000,000 incentive target.
The company reaffirmed projected full‑year 2026 consolidated adjusted income from operations of at least $30.25 per share, along with Evernorth pre‑tax adjusted income from operations of at least $6.9 billion and Cigna Healthcare pre‑tax adjusted income from operations of at least $4.5 billion, using its non‑GAAP adjusted income from operations metric.
The Cigna Group filed an update affirming its outlook for 2026. Company officials expect full-year 2026 consolidated adjusted income from operations of at least $30.25 per share, and plan to communicate this reaffirmed guidance in upcoming meetings with investors and analysts.
The filing explains that adjusted income from operations is a non-GAAP profit measure that starts from shareholders’ net income and removes net investment gains or losses, amortization of acquired intangibles, special items, and certain joint venture investment results. It emphasizes that this metric is used internally to analyze underlying business performance and trends.
The company notes it cannot reasonably reconcile this forward-looking non-GAAP measure to GAAP shareholders’ net income because future investment results and special items are unpredictable and may vary materially. Extensive cautionary language highlights risks such as healthcare cost trends, regulatory changes, technology and cybersecurity issues, economic conditions, and execution on strategic initiatives, all of which could cause actual results to differ from the outlook.
The Cigna Group filed its annual report describing a large, diversified global health business built around two main segments: Evernorth Health Services and Cigna Healthcare. Evernorth provides pharmacy benefit management, specialty pharmacy, care services and a new transparent, rebate-free pharmacy model that will begin rolling out in 2027–2028. Cigna Healthcare offers medical plans and related benefits in the U.S. and internationally, largely through self-funded employer arrangements.
The company serves more than 185 million customer relationships across over 30 markets with about 67,700 employees, mostly in the U.S. One pharmacy benefit client generated 19% of 2025 external revenue, and U.S. federal agencies contributed 11% of 2024 revenue. The aggregate market value of voting stock held by non‑affiliates was about $88.0 billion as of June 30, 2025, and 263,528,277 common shares were outstanding as of January 30, 2026. The filing also details extensive regulatory exposure, including recent federal legislation affecting pharmacy benefit managers, Affordable Care Act changes, privacy and cybersecurity rules, and the company’s governance framework for artificial intelligence and cybersecurity.
A CI shareholder filed a Form 144 notice to sell 6,109 shares of common stock through Fidelity Brokerage Services LLC on 02/06/2026 on the NYSE, with an aggregate market value of $1,791,895.21.
The filing shows these shares were acquired from the issuer as compensation: 539 shares from restricted stock vesting dated 04/24/2024, and 5,570 shares from a compensation grant dated 01/02/2026. Shares outstanding were 267,125,816 at the time referenced, providing scale for the planned sale.
The Cigna Group filed a current report to note that it issued a press release on February 5, 2026, covering its results for the three months and year ended December 31, 2025. The press release is attached as Exhibit 99.1 and is treated as furnished, not filed, under securities laws.